DNLI – denali therapeutics inc. (US:NASDAQ)
Stock Stats
News
4/7
08:02 am
dnli
Low
Denali Therapeutics (DNLI) had its price target raised by Robert W. Baird from $32.00 to $34.00. They now have an "outperform" rating on the stock.
4/3
02:11 pm
dnli
Low
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) [Yahoo! Finance]
4/3
01:30 pm
dnli
Low
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
4/1
11:58 am
dnli
Low
This rare disease destroys a child's ability to walk and speak. Could a new drug help? [MSNBC.com]
4/1
05:58 am
dnli
Low
They're in a race to save their children with a rare disease. A newly approved drug has given them hope. [MSNBC.com]
2/26/2026
04:01 pm
dnli
-1.1%
BEAT
11/6/2025
04:01 pm
dnli
1.2%
BEAT
8/11/2025
04:01 pm
dnli
0.7%
BEAT
5/6/2025
04:01 pm
dnli
2.5%
MISS
4/7
06:47 am
Maintains
Outperform
Outperform
Baird
Low
-0.3%
4/7
06:47 am
Maintains
Outperform
Outperform
Baird
Low
-0.3%
3/26
01:44 pm
Maintains
Overweight
Overweight
Morgan Stanley
Low
-2.4%
3/26
01:44 pm
Maintains
Overweight
Overweight
Morgan Stanley
Low
-2.4%
3/26
11:35 am
Maintains
Buy
Buy
Goldman Sachs
Medium
-4.0%
4/3
02:44 pm
dnli
Low
Form 8-K Denali Therapeutics Inc. For: Apr 03
3/31
08:30 am
dnli
Medium
Form 8-K Denali Therapeutics Inc. For: Mar 27
3/26
06:07 pm
dnli
Medium
Form SCHEDULE 13G/A Denali Therapeutics Inc. Filed by: VANGUARD GROUP INC
3/25
03:13 pm
dnli
Low
Form 8-K Denali Therapeutics Inc. For: Mar 25
2/26
04:16 pm
dnli
Low
Form 10-K Denali Therapeutics Inc. For: Dec 31
Show more
Top News Gainers
1/14 Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease 29.4%
1/26 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Goldman Sachs Group Inc from a "neutral" rating to a "buy" rating. 13.7%
4/1 Form 4/A Denali Therapeutics Inc. For: Feb 08 Filed by: Watts Ryan J. 8.9%
3/13 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Evercore ISI to an "outperform" rating. 7.9%
7/2 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $23.00 price target on the stock. 6.2%
10/21 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 5.7%
1/30 Goldman Sachs: These 2 Stocks Are Poised to Surge by at Least 35% [Yahoo! Finance News] 5.3%
12/3 30 Under 30 2020: Meet The Sports World’s Brightest Young Stars [Forbes] 4.6%
6/15 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at TheStreet from a "c-" rating to a "d" rating. 4.5%
11/26 Form 4 Denali Therapeutics Inc. For: Nov 22 Filed by: Schuth Alexander O. 4.5%
Top News Decliners
2/26 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -12.1%
3/30 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $21.00 price target on the stock. -11.1%
1/27 Denali Therapeutics Announces Proposed Offering of Common Stock -10.0%
1/15 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -9.3%
9/25 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Wedbush. They set a "neutral" rating on the stock. -9.1%
2/24 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating and a $35.00 price target on the stock. -7.2%
5/10 Form 4/A Denali Therapeutics Inc. For: Apr 01 Filed by: Ho Carole -6.7%
1/29 Form 424B5 Denali Therapeutics Inc. -6.5%
3/12 Flagship Pioneering Announces the Launch of Repertoire Immune Medicines with Industry Veteran John G. Cox as Chief Executive Officer -6.2%
9/13 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Nomura. They set a "buy" rating on the stock. -5.9%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3